肺癌的免疫治疗进展

目前肺癌的治疗手段是以手术、放疗、化疗和靶向治疗为主的综合治疗,虽然患者的生存期已明显延长,但至今仍是全世界癌症相关死因的主要原因.不断揭示肺癌新的发病机制、探讨新的治疗策略,仍是该领域专家需要共同面对的世界性难题.早期的研究已经初步证明多种肿瘤疫苗、免疫检查点抑制剂、过继性免疫等对肺癌的有效性,目前部分研究已进入Ⅲ期临床.PD-1、PD-L1等免疫检查点抑制剂已批准进入临床并取得理想的效果.随着临床研究的不断开展,越来越多的数据表明,在肺癌的个体化、整体化的治疗策略中适时介入免疫治疗将使更多的肺癌患者获益.

Advances in immunotherapies for lung cancer

At present,the main therapy of lung cancer is comprehensive treatment which includes surgery,radiotherapy,chemotherapy and targeted therapy.Although the overall survival is significantly prolonged,it is still the main cause of cancer-related death around the world.Constantly revealing new pathogenesis of lung cancer and exploring new therapeutic strategies are still the worldwide problems which experts in the field face together.Early researches have preliminarily proved the effectiveness of a wide variety of tumor vaccines,immune checkpoint inhibitors and adoptive immune response,and parts of them have entered the phase Ⅲ clinical trials.PD-1,PD-L1 and other immune checkpoint inhibitors have been approved for clinical treatment and achieved satisfactory results.With the development of clinical research,extensive research data suggest that the timely intervention of immunotherapy with individualized and integrative therapeutic strategies will benefit more patients.